Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
about
Genetics of resistant hypertension: a novel pharmacogenomics phenotypePharmacogenomics discovery and implementation in genome-wide association studies eraDrug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE ConsortiumPharmGKB summary: Diuretics pathway, pharmacodynamics.Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.Cardiomyopathy and Worsened Ischemic Heart Failure in SM22-α Cre-Mediated Neuropilin-1 Null Mice: Dysregulation of PGC1α and Mitochondrial Homeostasis.Allele-Selective Transcriptome Recruitment to Polysomes Primed for Translation: Protein-Coding and Noncoding RNAs, and RNA Isoforms.TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics.Genomics and Pharmacogenomics of Salt-sensitive HypertensionThe effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study.Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.Pharmacogenomics in clinical practice and drug development.Deep-targeted exon sequencing reveals renal polymorphisms associate with postexercise hypotension among African Americans.PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.Renin-angiotensin system blocking drugs.An update on the pharmacogenetics of treating hypertension.Exploring hypertension genome-wide association studies findings and impact on pathophysiology, pathways, and pharmacogenetics.Common genetic risk factors for coronary artery disease: new opportunities for prevention?Pharmacogenomics considerations in the control of hypertension.Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer's disease.Personalized medicine: Genetic risk prediction of drug response.Research Needs to Improve Hypertension Treatment and Control in African Americans.Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study.Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension.Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease.Applicability of Precision Medicine Approaches to Managing Hypertension in Rural Populations.Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study.Genomics and Pharmacogenomics of Salt-sensitive Hypertension.Hypertension genomics and cardiovascular prevention
P2860
Q26851506-B7317A57-B658-4B33-8DFA-92ADDA167D03Q27001573-A39C2F2C-5F26-46DD-9991-350C72A71152Q28550578-09C1950C-2F61-4AC7-B3E1-0A0A3922F04DQ33855431-CA3EC4F2-A604-4F40-BC9A-91BBE3970468Q35088179-5EB38CDF-4AB6-48E3-AF44-F4FD756035BCQ35565624-885F96AA-35A9-4C8C-AFE8-18184114BE14Q35637897-2D830AB5-27BE-44A9-A41B-A49707914822Q35762077-1B6FE8FC-2D8E-4DA0-B722-D4DCBAFFE958Q35794752-7F3BA828-8CD4-4147-887E-84C408441292Q36362642-53B2EFE9-FBED-46B7-93BC-60CF66FD2563Q36923553-97CA763D-8E89-47E5-9DB4-7FB4BD3630C1Q37116230-5C10FB97-76E9-42EA-BBEC-9F63E6A912B9Q37192199-A2C89AC3-5AB2-4D03-9F48-9DF23DAECCE9Q37284234-B06D7F62-E447-4DDC-B315-D0D835540D88Q37339260-B3187E2C-817B-494B-8BE7-9F13CCB2E288Q37622386-A54A858F-B46F-4813-A04C-1521CDA0DF19Q38137851-FE69549A-9C41-44CC-A19B-625DB5DA070AQ38263731-AFAA9943-B3C9-4ABA-95A3-7510143FED43Q38345519-0DF28B0A-F3E7-42B5-8DE7-013CBDB3F541Q38567857-52E2E49F-DD0E-4879-8A5F-EDCD4B82AE26Q38629883-B10410D9-FBC5-4537-98D4-2B365CF00C81Q38662596-EE2E4E4D-ADA4-41EF-A4D3-DC6B50551580Q38756015-396FA46D-4EEF-43EE-9543-AF84C0ED96FEQ39589011-0102D218-0C66-47A1-B93B-BA1411A14206Q45224072-77CCEA7A-308F-419A-96EA-E848AE98C91AQ47168939-118C6857-612A-43F6-9EF8-6B9ACB4BD29DQ52690281-E932A43F-47D2-49A3-B301-F86E99ADA001Q53687828-C8396612-3746-4632-AFD4-69C009C0B141Q55070146-95870893-065E-450C-A1F9-860526696B1CQ55076287-8D643672-117B-43F1-9B3E-A896C1AE428CQ58804798-AF47ED85-C1A1-48CC-AB46-EE0CA1E9FDA4
P2860
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Genomic association analysis i ...... giotensin II receptor blocker.
@ast
Genomic association analysis i ...... giotensin II receptor blocker.
@en
type
label
Genomic association analysis i ...... giotensin II receptor blocker.
@ast
Genomic association analysis i ...... giotensin II receptor blocker.
@en
prefLabel
Genomic association analysis i ...... giotensin II receptor blocker.
@ast
Genomic association analysis i ...... giotensin II receptor blocker.
@en
P2093
P2860
P1433
P1476
Genomic association analysis i ...... giotensin II receptor blocker.
@en
P2093
Arlene B Chapman
Gary L Schwartz
High Seng Chai
Kent R Bailey
Stephen T Turner
P2860
P304
P356
10.1161/HYP.0B013E31825B30F8
P407
P577
2012-05-07T00:00:00Z